This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): TMB-355, TNX-355, Hu5A8
Description: TNX-355 is a humanized anti-CD4 antibody selected to allow CD4 function while simultaneously inhibiting entry of HIV into CD4+ T cells. TNX-355 inhibits a confirmation change in CD4 that is necessary to allow entry of HIV into T cells. Via this mechanism of action, it has the potential to block the spread of HIV.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Tanox and Biogen
In 1998, Tanox obtained an exclusive license from Biogen to develop TNX-355. Biogen agreed to receive up to $10.4 million in milestone payments and royalties from sales of the drug.
Genentech and Tanox
In August 2007, Genentech completed the acquisition of Tanox.
Genentech and TaiMed
In September 2007, TaiMed Biologics licensed TNX-355 from Genentech and will take the lead on its development. Genentech will receive milestone payments and royalties should TNX-355 be approved and marketed.
Genentech and Roche
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009....See full deal structure in Biomedtracker
Partners: Biogen, Inc. Roche Holding AG TaiMed Biologics
Additional information available to subscribers only: